- Home
- ZH vs BCYC Comparison
ZH vs BCYC Comparison
Compare ZH & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZH
- BCYC
- Stock Information
- Founded
- ZH 2011
- BCYC 2009
- Country
- ZH China
- BCYC United Kingdom
- Employees
- ZH N/A
- BCYC N/A
- Industry
- ZH Business Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ZH Consumer Discretionary
- BCYC Health Care
- Exchange
- ZH Nasdaq
- BCYC Nasdaq
- Market Cap
- ZH 421.4M
- BCYC 492.1M
- IPO Year
- ZH 2021
- BCYC 2019
- Fundamental
- Price
- ZH $5.16
- BCYC $7.00
- Analyst Decision
- ZH Strong Buy
- BCYC Buy
- Analyst Count
- ZH 1
- BCYC 11
- Target Price
- ZH $4.70
- BCYC $22.91
- AVG Volume (30 Days)
- ZH 385.3K
- BCYC 213.9K
- Earning Date
- ZH 08-27-2025
- BCYC 10-30-2025
- Dividend Yield
- ZH N/A
- BCYC N/A
- EPS Growth
- ZH N/A
- BCYC N/A
- EPS
- ZH 0.22
- BCYC N/A
- Revenue
- ZH $439,821,184.00
- BCYC $19,281,000.00
- Revenue This Year
- ZH N/A
- BCYC N/A
- Revenue Next Year
- ZH $6.47
- BCYC N/A
- P/E Ratio
- ZH $23.61
- BCYC N/A
- Revenue Growth
- ZH N/A
- BCYC N/A
- 52 Week Low
- ZH $3.13
- BCYC $6.10
- 52 Week High
- ZH $6.32
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- ZH 58.76
- BCYC 44.07
- Support Level
- ZH $4.64
- BCYC $6.77
- Resistance Level
- ZH $5.55
- BCYC $7.32
- Average True Range (ATR)
- ZH 0.20
- BCYC 0.38
- MACD
- ZH 0.01
- BCYC 0.02
- Stochastic Oscillator
- ZH 57.14
- BCYC 28.00
About ZH Zhihu Inc. (every two of each representing one ordinary share)
Zhihu Inc is predominantly engaged in the operation of one online content community and monetizes through paid membership services, advertising services, content-commerce solutions services, and vocational training in China. It generates revenues from Advertising services, Paid membership services, Content-commerce solutions, and Others. It derives all its revenues within China.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.